DEFA14A: Leap Therapeutics Announces 2025 Annual Meeting of Shareholders

Leap Therapeutics will hold its annual shareholder meeting virtually on June 18, 2025, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Leap Therapeutics, Inc. will hold its 2025 Annual Meeting of Shareholders virtually on June 18, 2025.
• Shareholders will vote on three proposals: electing three directors, approving executive compensation in a non-binding advisory vote, and ratifying the appointment of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting FOR all director nominees and FOR the proposals regarding executive compensation and auditor ratification.
• Shareholders can vote online, via smartphone/tablet using a QR code, or during the virtual meeting using a 12-digit control number.
• Proxy materials, including the annual report for the year ended December 31, 2024, the proxy statement, and the proxy card, are available online.
• Shareholders can request a paper or e-mail copy of the proxy materials free of charge by June 4, 2025.

Sentiment

Score: 7

Explanation: The document is a routine announcement of an upcoming shareholder meeting, with standard proposals. The tone is neutral and informative, reflecting typical corporate communication.

Positives

• Shareholders have multiple convenient options for voting, including online, mobile, and during the virtual meeting.
• The Board of Directors is providing clear recommendations on how to vote on each proposal.

Future Outlook

The document outlines the agenda for the upcoming annual meeting, focusing on key governance matters and providing shareholders with the opportunity to influence the company's direction through their votes.

Management Comments

• The Board of Directors recommends a vote FOR all nominees under Proposal 1, and FOR Proposals 2 and 3.

Industry Context

This announcement is a standard part of corporate governance, ensuring shareholders have a voice in key decisions such as electing directors, approving executive compensation, and selecting the company's auditor. It aligns with typical practices for publicly traded companies.

Comparison to Industry Standards

• Holding an annual shareholder meeting is standard practice for publicly traded companies like Leap Therapeutics.
• The proposals being voted on (director elections, executive compensation, auditor ratification) are typical agenda items for such meetings.
• Providing multiple voting options (online, mobile, in-person) is increasingly common to encourage shareholder participation.
• The virtual format of the meeting aligns with a growing trend in corporate governance, especially post-pandemic.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction by voting on key proposals.
• The outcome of the votes will impact the composition of the Board of Directors, executive compensation, and the selection of the company's auditor.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals before the June 18, 2025 meeting.
• The company will hold the virtual annual meeting on June 18, 2025, to conduct the voting and address shareholder questions.

Key Dates

Keywords

Annual Meeting, Shareholders, Proxy Statement, Leap Therapeutics, Voting, Directors, Executive Compensation, Auditor Ratification